Genesis Capital, a private equity firm, completed the investment in P3 Research, a clinical trials site network. Financial terms were not disclosed. "New Zealand has become increasingly a destination of choice for the global clinical trials industry. With Genesis now on board, we look forward to being able to further expand our high-quality service capability with new sites catering to new and expanded therapeutic areas for our clients, while increasing patient access to the latest ground-breaking therapies across a broad range of disease states," Richard Stubbs, P3 Research CEO.